Molecular gene signature and prognosis of non-small cell lung cancer

The current staging system for non–small cell lung cancer (NSCLC) is inadequate for predicting outcome. Risk score, a linear combination of the values for the expression of each gene multiplied by a weighting value which was estimated from univariate Cox proportional hazard regression, can be useful. The aim of this study is to analyze survival-related genes with TaqMan Low-Density Array (TLDA) and risk score to explore gene-signature in lung cancer. A total of 96 NSCLC specimens were collected and randomly assigned to a training (n = 48) or a testing cohort (n = 48). A panel of 219 survival-associated genes from published studies were used to develop a 6-gene risk score. The risk score was used to classify patients into high or low-risk signature and survival analysis was performed. Cox models were used to evaluate independent prognostic factors. A 6-gene signature including ABCC4, ADRBK2, KLHL23, PDS5A, UHRF1 and ZNF551 was identified. The risk score in both training (HR = 3.14, 95% CI: 1.14–8.67, p = 0.03) and testing cohorts (HR = 5.42, 95% CI: 1.56–18.84, p = 0.01) was the independent prognostic factor. In merged public datasets including GSE50081, GSE30219, GSE31210, GSE19188, GSE37745, GSE3141 and GSE31908, the risk score (HR = 1.50, 95% CI: 1.25–1.80, p < 0.0001) was also the independent prognostic factor. The risk score generated from expression of a small number of genes did perform well in predicting overall survival and may be useful in routine clinical practice.

[1]  M. Pepe,et al.  Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. , 2004, American journal of epidemiology.

[2]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[3]  Y. Miller.  Pathogenesis of lung cancer: 100 year report. , 2005, American journal of respiratory cell and molecular biology.

[4]  C. Vedeler,et al.  Detection of Autoantibodies to the BTB‐kelch Protein KLHL7 in Cancer Sera , 2006, Scandinavian journal of immunology.

[5]  N. Voelkel,et al.  Gene expression profiling in pulmonary hypertension. , 2007, Proceedings of the American Thoracic Society.

[6]  Katrien Van Roosbroeck,et al.  PDS5A, a novel translocation partner of MLL in acute myeloid leukemia. , 2012, Leukemia research.

[7]  P. He,et al.  Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[9]  Sridhar Ramaswamy,et al.  Translating cancer genomics into clinical oncology. , 2004, The New England journal of medicine.

[10]  A. Marchetti,et al.  Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. , 2007, The Journal of clinical investigation.

[11]  K. Schmid,et al.  Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study , 2014, Modern Pathology.

[12]  Eun Sung Park,et al.  Development and Validation of a Prognostic Gene-Expression Signature for Lung Adenocarcinoma , 2012, PloS one.

[13]  K. Izuhara,et al.  Microarray-based identification of novel biomarkers in asthma. , 2006, Allergology international : official journal of the Japanese Society of Allergology.

[14]  Yue Wang,et al.  ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer , 2014, OncoTargets and therapy.

[15]  M. Ringnér,et al.  Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks , 2001, Nature Medicine.

[16]  J. O’Shaughnessy,et al.  Molecular signatures predict outcomes of breast cancer. , 2006, The New England journal of medicine.

[17]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[18]  Hushan Yang,et al.  Genetic variations in SLC3A2/CD98 gene as prognosis predictors in non‐small cell lung cancer , 2015, Molecular carcinogenesis.

[19]  E. Otero-Rey,et al.  Activity of β2-adrenergic receptor in oral squamous cell carcinoma is mediated by overexpression of the ADRBK2 gene: a pilot study , 2012, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[20]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[21]  T. Chou,et al.  Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[22]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[23]  Zoltan Szallasi,et al.  A robust prognostic gene expression signature for early stage lung adenocarcinoma , 2016, Biomarker Research.

[24]  R. Salgia,et al.  A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. , 2014, Advances in experimental medicine and biology.

[25]  M. Socinski,et al.  Personalizing Therapy in Advanced Non–Small Cell Lung Cancer , 2013, Seminars in Respiratory and Critical Care Medicine.

[26]  Tianhong Li,et al.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[28]  Elisabeth Brambilla,et al.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.

[29]  J. Hoheisel.  Microarray technology: beyond transcript profiling and genotype analysis , 2006, Nature Reviews Microbiology.

[30]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[31]  Zhifu Sun,et al.  Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[33]  T. Liloglou,et al.  UHRF1‐mediated tumor suppressor gene inactivation in nonsmall cell lung cancer , 2011, Cancer.

[34]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[36]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[37]  T. Mitsudomi,et al.  Personalized therapy on the horizon for squamous cell carcinoma of the lung. , 2013, Lung cancer.

[38]  Jeremy J. W. Chen,et al.  Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. López-Ríos,et al.  MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer , 2014, PloS one.

[40]  D. Walther,et al.  Gene Expression Profiles and B-Type Natriuretic Peptide Elevation in Heart Transplantation: More Than a Hemodynamic Marker , 2006, Circulation.

[41]  Y. Yatabe,et al.  Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[43]  H. Dressman,et al.  Genomic signatures to guide the use of chemotherapeutics , 2006, Nature Medicine.

[44]  Ker-Chau Li,et al.  EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma , 2016, Oncotarget.

[45]  Igor Jurisica,et al.  Three-gene prognostic classifier for early-stage non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Minna,et al.  Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines , 2016, PloS one.

[47]  J. Ware.  The limitations of risk factors as prognostic tools. , 2006, The New England journal of medicine.

[48]  M. Tyers,et al.  Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. , 2002, Cancer research.